Azole Antifungal Resistance in Candida albicans and Candida glabrata Isolated from Vulvovaginal Candidiasis Patients

AUTHORS

Niloofar Deravi ORCID 1 , Mobina Fathi ORCID 1 , Seyede Nadia Tabatabaeifar 2 , Parichehr Pooransari 3 , Bahram Ahmadi 4 , Gholamreza Shokoohi ORCID 5 , Shirin Yaghoobpoor 1 , Kimia Vakili 1 , Ensieh Lotfali ORCID 6 , Saham Ansari ORCID 6 , *

1 Medical Student Research, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Department of Internal Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran

3 Department of Obstetrics and Gynecology, Shohada Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Department of Medical Laboratory Sciences, School of Para-Medicine, Bushehr University of Medical Sciences, Bushehr, Iran

5 Department of Medical Parasitology and Mycology, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran

6 Department of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

How to Cite: Deravi N, Fathi M, Tabatabaeifar S N , Pooransari P , Ahmadi B, et al. Azole Antifungal Resistance in Candida albicans and Candida glabrata Isolated from Vulvovaginal Candidiasis Patients, Arch Clin Infect Dis.2021 In Press(In Press): e106360. doi: 10.5812/archcid.106360.

ARTICLE INFORMATION

Archives of Clinical Infectious Diseases: In Press (In Press); e106360
Published Online: June 05, 2021
Article Type: Research Article
Received: June 12, 2020
Revised: March 28, 2021
Accepted: April 11, 2021
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

Background: Vulvovaginal candidiasis (VVC), is the most frequent fungal disorder in healthy and normal women.

Objectives: The aim of this study was to evaluate the in vitro antifungal susceptibility of clinical isolates Candida albicans and Candida glabrata, the two most common candida species in Iranian VVC patients.

Methods: One hundred and eight clinical isolates of candida including; C. albicans (n=77) and C. glabrata: (n=31) were isolated from the 108 patients with VVC. The in vitro activity of caspofungin (CAS), amphotericin B (AMB), voriconazole (VRC), itraconazole (ITC), fluconazole (FLC), and nystatin (NYS) were determined according to the CLSI M27-A3 and CLSI M27-S4.

Results: Our results were shown 8 (25.8 %) and 6 (7.8 %) C. glabrata and C. albicans isolates resistance to FLU respectively. Furthermore, resistence to VRC and ITC were observed in 8.4% and 3.7% of all isolates and six isolates (5.6%) had intermediate MIC to CAS.

Conclusion: We reported 8 (25.8 %) and 6 (7.8 %) C. glabrata and C. albicans isolates resistance to FLU respectively. Furthermore, resistence to VRC and ITC were observed in 8.4% and 3.7% of all isolates.

Fulltext

© 2021, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: